Northwest Biotherapeutics, Inc. (NWBO)

Northwest Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	1.34	1.93	1.68	1.01	1.29	2.41
Revenue Growth (YoY)	-38.15%	14.80%	67.46%	-22.15%	-46.43%	484.95%
Cost of Revenue	1.84	1.73	1.55	20.31	33.64	14.11
Gross Profit	-0.5	0.2	0.14	-19.3	-32.35	-11.7
Selling, General & Admin	29.89	27.98	33.35	33.4	54.26	16.28
Research & Development	28.81	27.73	35.51	20.31	33.64	13.59
Other Operating Expenses	1.72	-0.08	0.03	-0.65	0	0
Operating Expenses	58.7	55.71	68.86	53.71	87.9	29.87
Operating Income	-58.29	-55.51	-67.18	-52.7	-86.61	-27.46
Interest Income	-1.03	0	6.07	5.01	8.54	2.98
Interest Expense	2.39	5.53	6.07	5.01	8.54	2.98
Other Expense / Income	8.18	1.56	37.85	-236.19	443.22	-7.17
Pretax Income	-70.78	-62.6	-105.03	179.13	-529.82	-20.3
Income Tax	0.89	0	31.82	4.36	8.54	3.28
Net Income	-70.78	-62.6	-136.85	179.13	-538.37	-23.57
Shares Outstanding (Basic)	1,188	1,119	1,016	874	725	564
Shares Outstanding (Diluted)	1,188	1,119	1,016	1,008	725	564
Shares Change	10.54%	10.17%	0.79%	38.99%	28.53%	28.22%
EPS (Basic)	-0.06	-0.06	-0.13	0.21	-0.74	-0.04
EPS (Diluted)	-0.06	-0.06	-0.13	-0.06	-0.74	-0.04
Free Cash Flow	-57.15	-57.07	-55.68	-44.31	-38.7	-32.22
Free Cash Flow Per Share	-0.05	-0.05	-0.05	-0.04	-0.05	-0.06
Gross Margin	-37.43%	10.30%	8.02%	-1920.70%	-2505.50%	-485.31%
Operating Margin	-4362.87%	-2873.08%	-3991.74%	-5243.98%	-6708.37%	-1139.54%
Profit Margin	-5297.75%	-3240.11%	-8131.19%	17823.48%	-41701.39%	-978.09%
Free Cash Flow Margin	-4277.47%	-2954.14%	-3308.20%	-4409.35%	-2997.91%	-1336.89%
Effective Tax Rate	-	-	-	2.44%	-	-
EBITDA	-56.84	-53.78	-65.65	-52.76	-86.18	-27.46
EBITDA Margin	-4254.64%	-2783.39%	-3900.65%	-5250.05%	-6675.45%	-1139.54%
Depreciation & Amortization	1.84	1.73	1.5	0.59	0.43	-0.3
EBIT	-58.68	-55.51	-67.15	-53.35	-86.61	-27.16
EBIT Margin	-4392.07%	-2873.08%	-3989.78%	-5308.36%	-6708.37%	-1127.05%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.